

IX BIOPHARMA LTD.
(Company Registration Number 200405621W)
(Incorporated in the Republic of Singapore)

PROPOSED ISSUANCE OF CONVERTIBLE BONDS OF AN AGGREGATE PRINCIPAL AMOUNT OF S\$2,000,000

- COMPLETION

The Board of Directors (the "**Board**") of iX Biopharma Ltd (the "**Company**", and collectively with its subsidiaries, the "**Group**") refers to its announcements dated 3 July 2023 and 17 July 2023 (the "**Previous Announcements**") in respect of issuance of S\$2,000,000 in principal amount of interest-bearing convertible bonds, which are convertible into new ordinary shares in the capital of the Company (the "**Proposed CB Issuance**").

Unless otherwise stated, all capitalised terms used herein shall bear the same meanings as ascribed to them in the Previous Announcements.

The Board is pleased to announce that the conditions precedent pursuant to the Subscription Agreement have been fulfilled, and the Proposed CB Issuance has been completed. The Subscriber has been issued the Bonds in the aggregate principal amount of S\$2 million in accordance with the terms of the Subscription Agreement.

By Order of the Board

Gwendolin Lee Soo Fern/Lai Kuan Loong, Victor
Company Secretaries

24 July 2023

This announcement has been prepared by the Company and its contents have been reviewed by the Company's Sponsor, UOB Kay Hian Private Limited (the "Sponsor") for compliance with the relevant rules of the Singapore Exchange Securities Trading Limited ("SGX-ST") Listing Manual Section B: Rules of Catalyst.

This announcement has not been examined or approved by the SGX-ST and the SGX-ST assumes no responsibility for the contents of this announcement, including the accuracy, completeness or correctness of any of the information, statements or opinions made or reports contained in this announcement.

The contact person for the Sponsor is Mr. Lance Tan, Senior Vice President, at 8 Anthony Road, #01-01, Singapore 229957, telephone: (65) 6590 6881.